Figure 6.

From the GESUS screening of 19,958 citizens in the Zealand region of Denmark the prevalence of having acquired a malignant JAK2V617F mutation is calculated. The prevalence in percentages is stratified into age decades (shown in squared bracket on the x-axis) as shown by blue dots with standard deviation given by the red whiskers. The cyan-colored line is the best linear fit to data neglecting the first and last data points. The best fit has a slope of approximately 0.1%. Thus, the prevalence increases approximately linearly with 0.1% per year or 1% per decade. Adopted from [19].